MICB抗体;MICB Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of THP-1 cells using MICB mouse mAb (green) and negative control (red).    

  
  

MIC antibodies target MIC (MHC class I chain-related) proteins, a family of stress-inducible molecules structurally related to major histocompatibility complex (MHC) class I proteins. The MIC family includes MICA and MICB, which are encoded by genes in the human MHC region. Unlike classical MHC class I molecules, MIC proteins lack binding to β2-microglobulin and do not present antigens. Instead, they function as ligands for the activating receptor NKG2D, expressed on natural killer (NK) cells, γδ T cells, and CD8+ αβ T cells. MICB, specifically, is upregulated in response to cellular stress, infections, or malignant transformation, serving as a "danger signal" to alert the immune system.

Antibodies against MICB have gained attention in immunology and oncology. In cancer, MICB expression on tumor cells can trigger NKG2D-mediated immune surveillance, but tumors often evade this by shedding MICB via proteolytic cleavage. Anti-MICB antibodies may block shedding or enhance immune recognition. Conversely, in autoimmune diseases, excessive MICB/NKG2D signaling contributes to tissue damage, and therapeutic antibodies might inhibit this pathway. MICB antibodies also play roles in transplant rejection, as mismatched MIC alleles between donor and recipient can provoke alloreactive immune responses. Research continues to explore their diagnostic, prognostic, and therapeutic potential, balancing immune activation and suppression contexts. Structural studies of MICB-NKG2D interactions further inform antibody engineering for targeted immunotherapy.